Abstract
In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non insulin dependent diabetes mellitus (NIDDM or Type 2 diabetes) is a prevalent, chronic metabolic disorder, which affects more than 171 million people worldwide. Diminished insulin secretion due to impaired cell function and or insulin resistance of the peripheral tissues such as liver, adipose tissue and skeletal muscle causes hyperglycemia, which is controlled with suitable pharmacological agents. The current line of treatment includes: (1) insulin secretagogues, (2) insulin sensitizers, (3) dipeptidyl peptidase IV inhibitors, (4) biguanides, (5) glucosidase inhibitors and (6) drugs in development.
Keywords: Oral Hypoglycemics, metabolic syndromeNon insulin dependent diabetes mellitus (NIDDM), chronic metabolic disorder, hyperglycemia, insulin sensitizers, biguanides
Current Bioactive Compounds
Title: Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Volume: 4 Issue: 2
Author(s): S. W. Zito, J. Shinde, I C. S. Chen, T. Taldone and M. Barletta
Affiliation:
Keywords: Oral Hypoglycemics, metabolic syndromeNon insulin dependent diabetes mellitus (NIDDM), chronic metabolic disorder, hyperglycemia, insulin sensitizers, biguanides
Abstract: In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non insulin dependent diabetes mellitus (NIDDM or Type 2 diabetes) is a prevalent, chronic metabolic disorder, which affects more than 171 million people worldwide. Diminished insulin secretion due to impaired cell function and or insulin resistance of the peripheral tissues such as liver, adipose tissue and skeletal muscle causes hyperglycemia, which is controlled with suitable pharmacological agents. The current line of treatment includes: (1) insulin secretagogues, (2) insulin sensitizers, (3) dipeptidyl peptidase IV inhibitors, (4) biguanides, (5) glucosidase inhibitors and (6) drugs in development.
Export Options
About this article
Cite this article as:
Zito W. S., Shinde J., Chen S. I C., Taldone T. and Barletta M., Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294190
DOI https://dx.doi.org/10.2174/157340708785294190 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry New Approaches to Providing Individualized Diabetes Care in the 21st Century
Current Diabetes Reviews The Association between Metabolic Syndrome and Serum Levels of Adiponectin and High Sensitive C Reactive Protein in Gorgan
Endocrine, Metabolic & Immune Disorders - Drug Targets Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Transient Receptor Potential A1 Modulators
Current Topics in Medicinal Chemistry The Study on the Active Ingredients and Potential Targets of Rice Bran Petroleum Ether Extracts for Treating Diabetes Based on Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Evaluation of the Pharmacodynamic Activity of Insulin from Bilosomal Formulation
Current Drug Delivery Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches
Current Pharmaceutical Design NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews D Allele Frequency in Insertion/Deletion Polymorphism of the Angiotensin Converting Enzyme (ACE) Gene is Associated with Development of Breast Cancer Risk in Indian Women
Current Proteomics Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Current Pharmaceutical Design Variation of Pharmacokinetic Profiles of Some Antidiabetic Drugs from Nanostructured Formulations Administered Through Pulmonary Route
Current Drug Metabolism